Three new drugs for hyperlipidemia.
D001384:Azetidines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D000069438:Ezetimibe; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D007408:Intestinal Absorption / Q000187:drug effects; D008148:Lovastatin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D009135:Muscular Diseases / Q000139:chemically induced; D009525:Niacin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use
D001384:Azetidines; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D000960:Hypolipidemic Agents; C451780:lovastatin-niacin combination; D009525:Niacin; D008148:Lovastatin; D000069438:Ezetimibe